BFRI - Biofrontera reports preliminary Q2 revenues $5.7M-$5.9M

2023-07-13 14:15:50 ET

• Biofrontera ( NASDAQ: BFRI ) has announced preliminary revenues for Q2 2023 to be in the range of ~$5.7M to $5.9M vs. consensus of $6.78M , an increase of ~26% to 31% Y/Y.
• As a result, revenues for the first half of 2023 are anticipated to be in the range of ~$14.4M to $14.6M, representing growth of ~1% to 3% compared with the first half of 2022.
• Reaffirms its previously announced expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022.
• "We are proud of the hard work of our commercial teams, which resulted in year-over-year revenue growth without the benefit of a price increase for Ameluz® as we had in 2022." said Hermann Luebbert, CEOr and Chairman.

For further details see: